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Although the introduction of Her2-targeted therapies improved the outcome of Her2+ breast cancer, 41 
many patients experience resistance and metastatic progression despite treatment. Since cancer stem 42 
cell (CSCs) play a role in this mechanism, the development of therapies combining Her2-targeting 43 
with CSC inhibition could improve the management of Her2+ breast cancer. We previously 44 
demonstrated that the cystine-glutamate antiporter xCT is overexpressed in mammary CSCs and is 45 
crucial for their redox balance, self-renewal and resistance to therapies, representing a promising 46 
target for breast cancer immunotherapy. 47 
Here, we developed a combined immunotherapy targeting Her2 and xCT using the Bovine Herpes 48 
virus (BoHV)-4 vector, a safe vaccine that can confer immunogenicity to tumor antigens. Mammary 49 
cancer-prone BALB-neuT mice, transgenic for rat Her2, were immunized with the single or combined 50 
vaccines. Anti-Her2 vaccination mostly affected primary tumor by significantly slowing down 51 
mammary cancer growth, while anti-xCT vaccination primarily prevented metastasis formation. The 52 
combination of the two vaccines exerted a complementary effect. These activities were mediated by 53 
the induction of cytotoxic T cells and of specific anti-Her2 and anti-xCT antibodies that induce 54 
antibody-dependent cell cytotoxicity and hinder cancer cell proliferation. Antibodies targeting xCT, 55 
but not those targeting Her2, directly affected viability and self-renewal of CSCs as well as cell 56 
migration, inducing the anti-metastatic effect of xCT immunotargeting.  57 
Our findings open new perspectives in the management of Her2+ breast cancer, demonstrating that 58 
CSC immunotargeting through anti-xCT vaccination, by inhibiting metastasis formation that is not 59 




Breast cancer is, together with colon and lung cancers, one of the three most frequent cancers 62 
worldwide, and the most common in women. In the last years, its prognosis has improved, thanks to 63 
the progresses achieved in its early detection and therapy. However, it still represents the second 64 
cause of cancer deaths in developed countries, and its incidence and mortality are progressively 65 
increasing in Asia, Africa and South America (1).  66 
Roughly 20% of breast cancers worldwide show overexpression or amplification of the Her2 67 
oncogene. Although Her2 positivity is associated with poor prognosis and poor response to standard 68 
chemotherapies, the introduction of anti-Her2 monoclonal antibodies and inhibitors has improved 69 
disease free and overall survival of Her2+ breast cancer patients (2). However, most patients affected 70 
by metastatic disease display primary or secondary resistance to Her2-targeted therapies. This 71 
eventually leads to disease progression despite treatment, and advanced Her2+ breast cancer remains 72 
almost incurable (3). Therefore, the development of new therapeutic approaches able to increase the 73 
efficacy of Her2-targeting drugs is urgently needed.  74 
Breast cancer stem cells (CSCs) have been identified as one of the causes for primary resistance to 75 
Her2-targeted therapies, and their presence is a negative prognostic factor for sensitivity to the anti-76 
Her2 monoclonal antibody Trastuzumab (4). Therefore, CSC targeting may co-operate with Her2-77 
directed therapies and prevent the development of secondary resistance, resulting in improved 78 
patients’ outcome. In the last two decades, a huge effort has been devoted to identify novel CSC 79 
molecular targets and to develop new treatments able to eradicate these cells (5,6). 80 
We have previously demonstrated that xCT, a multipass transmembrane protein encoded by the gene 81 
SLC7A11, is overexpressed in breast CSCs and plays a key role in their self-renewal and resistance 82 
to therapy (7). xCT is the light chain of the antiporter system xc-, which mediates the cell uptake of 83 
cystine in exchange with glutamate. On one hand, glutamate released in the tumor microenvironment 84 
by xCT activates the suppressive function of T regulatory cells (Tregs) and promotes breast cancer 85 
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cell invasion (8,9). On the other hand, imported cystine is reduced to cysteine, the rate-limiting 86 
precursor in the synthesis of glutathione (GSH). GSH is the main intracellular anti-oxidant molecule 87 
that protects cells from ferroptosis, differentiation, autophagy, senescence and toxicity induced by 88 
xenobiotics such as chemotherapeutic drugs (10).  89 
xCT is poorly expressed in healthy tissues while overexpressed in different tumor types, including 90 
breast cancer of different histological subtypes, where its expression is particularly increased in CSCs 91 
(7,10). Indeed, the stem cell markers CD44v and Mucin-1 interact with xCT and stabilize it at the cell 92 
membrane (11). In breast cancer, xCT is overexpressed in atypical hyperplasia and invasive ductal 93 
carcinoma of different histological subtypes (7), and is linked to poor prognosis in triple negative 94 
breast cancer patients (12). Therefore, xCT is a promising target candidate for the development of 95 
combined therapies for breast cancer.  96 
Many authors have endorsed the pharmacological inhibition of xCT as a therapeutic strategy, and a 97 
variety of compounds have been investigated. Among them erastin (13) and the FDA-approved drugs 98 
sulfasalazine (SAS) (14) and sorafenib (13). However, erastin and SAS are insoluble under 99 
physiological conditions, have poor metabolic stability and pharmacokinetics, precluding their 100 
reliable use in vivo. In addition, SAS and sorafenib display low specificity for xCT, and are known 101 
for their ability to inhibit NF-kB and various kinases, respectively, and to induce important side 102 
effects (10,13,15). Therefore, new ways to specifically target xCT need to be developed for clinical 103 
use.  104 
Since immunotherapy represents a promising strategy for cancer treatment (16), we have previously 105 
developed different vaccine platforms to specifically target xCT-expressing breast CSCs. Using these 106 
vaccines we have demonstrated that xCT immunotargeting effectively impairs cancer growth and 107 
metastatic dissemination in syngeneic transplantable mouse models of breast cancer (7,17,18).  108 
As a proof of concept that xCT immunotargeting may ameliorate the efficacy of Her2-targeted 109 
therapies, here we develop a combined immunotherapy administering Bovine Herpes virus 4 (BoHV-110 
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4)-based vaccines targeting Her2 (BoHV-4-Her2) and xCT (BoHV-4-xCT) in a preclinical model of 111 
Her2+ mammary carcinogenesis, the BALB-neuT mice (19). BoHV-4 represents a promising 112 
vaccination strategy endowed with a high potential for clinical translatability, since it is a safe vector 113 
able to induce a strong immune response to heterologous antigens, breaking the immune tolerance 114 
towards cancer-associated antigens (17,20). Indeed, we have previously demonstrated that BoHV-4-115 
xCT is superior to other anti-xCT vaccines in inducing a specific immune response, since it is the 116 
only vector able to break the CD8+ T cell tolerance and induce xCT-specific cytotoxic T lymphocytes 117 
(7,10,17,18). We here demonstrate that the combination of Her2 and xCT-targeting synergistically 118 
impairs breast cancer progression, with anti-Her2 vaccine inducing an immune response able to 119 
hinder the growth of primary tumors, and anti-xCT immunotargeting impairing CSC survival and 120 
metastatic dissemination. 121 
 122 
Materials and Methods 123 
Cell and tumorsphere cultures 124 
SKBR3 and 4T1 cells were purchased from ATCC and cultured, respectively, in McCoy's 5A 125 
Modified Medium or RPMI (ThermoFisher Scientific) with 10% FBS (Sigma-Aldrich). TUBO cells 126 
were derived from BALB-neuT primary tumors (21) and cultured in DMEM (ThermoFisher 127 
Scientific) 20% FBS (21). All cells were tested negative for mycoplasma (22). Tumorspheres were 128 
generated and maintained as in (23). 129 
Vaccine generation and in vivo treatment  130 
BoHV-4-Her2 (alias BoHV-4-RHuT-gD), BoHV-4-xCT and the control vector BoHV-4-ctrl (alias 131 
BoHV-4-A29) were generate as previously described, and TCID50 determined by limiting dilution on 132 
BEK cells (17,20). Female BALB-neuT mice were generated and maintained at the Molecular 133 
Biotechnology Center, University of Torino, and treated in accordance with the University Ethical 134 
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Committee and European guidelines under Directive 2010/63. In vivo treatments were approved by 135 
the Italian Ministry of Health, authorizations N° 237/2015-PR and 500/2017-PR. Mice were 136 
vaccinated six times by intraperitoneus (i.p.) injection of 106 TCID50 of BoHV-4-ctrl, BoHV-4-xCT, 137 
and/or BoHV-4-Her2 at 2-week intervals, starting from 6 weeks of age; sera were collected at week 138 
14 and 18 (Fig. 1 B). Mice were inspected weekly and progressively growing masses with a mean 139 
diameter >1 mm were regarded as tumors. Growth was monitored until all 10 mammary glands 140 
displayed a tumor or a tumor exceeded a mean diameter of 10 mm, then mice were culled, and lungs, 141 
tumors, spleens and blood collected and processed for FACS analysis or storage. Superficial lung 142 
metastases were counted using a Zeiss SEMI DV4 Spot stereomicroscope. 143 
FACS analysis 144 
Tumorsphere-derived cells were incubated with sera from vaccinated mice for 5 days, then 145 
dissociated cells were stained with anti-Sca1-AlexaFluor647, anti-CD44-PE and anti-mouse CD24-146 
PE/Cy7 or anti-human CD24-FITC (Biolegend). To measure intracellular reactive oxygen species 147 
(ROS), cells were stained with 2′,7′-dihydrochlorofluorescein diacetate (Sigma-Aldrich) (7). 148 
Apoptosis was evaluated with the AnnexinV Apoptosis Kit APC (eBioscience) (24). 149 
To evaluate xCT expression, cells were fixed/permeabilized with BD Cytofix/Cytoperm kit and 150 
stained with anti-xCT rabbit antibody (PA1-16775, ThermoFisher) followed by FITC-anti-rabbit Ig 151 
(Dako). 152 
To analyze peripheral Tregs, heparinized blood was incubated in erythrocytes lysis buffer (155 mM 153 
NH4Cl, 15.8 mM Na2CO3, 1 mM EDTA, pH 7.3) 10 minutes R.T., treated with Fc receptor blocker 154 
(anti-CD16/CD32; BD Biosciences) and stained with anti-mouse-CD45-VioGreen (Miltenyi Biotec), 155 
CD4-PE/Cy7, GITR-PE and CD25-APC (Biolegend). Cells were washed, fixed/permeabilized and 156 
stained with anti-FoxP3-FITC (eBioscience) as in (25). 157 
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Single cell suspensions obtained from lungs and tumors were treated with Fc receptor blocker (26), 158 
and stained with the following Abs: anti-mouse CD45-VioGreen, CD3-FITC, CD4-APC/Vio770, 159 
CD8-VioBlue, PD-1-APC, CD49b-PE (Miltenyi Biotec), CD69-PE/Cy7, CD44-PE, CD24-PE/Cy7 160 
and Sca1-AlexaFluor647 as in (17). Samples were acquired on a BD FACSVerse and analyzed with 161 
FlowJO10.5.3. tSNE analysis of immune infiltrates was run on 5 samples per group. FCS3 files were 162 
downsampled to 5000 CD45+ live events, then combined into a single FCS3 file using the 163 
concatenation tool. tSNE analysis was run (perplexity, 30; iterations, 1,000), then samples were 164 
grouped according to experimental groups, and visualized in the dot plots. 165 
ELISA 166 
Mouse sera (1:50) were incubated on plates coated with either recombinant mouse xCT (Cloud-Clone 167 
Corp., 40 ng/well), extracellular rat or human Her2 (Sino Biological, 100 ng/well) proteins or mouse 168 
xCT extracellular loop peptides (GenScript, 1 µg/well), and binding detected with HRP-conjugated 169 
anti-mouse IgG Ab (17,20). 170 
Cytotoxicity 171 
1×104 4T1 or TUBO target cells stained with 2 µM CFSE (Molecular Probes) were cultured with 172 
splenocytes (SPC) at effector:target (E:T) ratios of 200:1, 100:1, and 50:1 for 48 h, stained with 1 173 
μg/ml 7-Amino-ActinomycinD (7-AAD, BD Biosciences), and analyzed by FACS (17). For 174 
antibody-dependent cell-mediated cytotoxicity (ADCC), E:T incubation was performed overnight in 175 
the presence of sera from vaccinated mice (1:50). % ADCC was calculated as in (17). 176 
Immune sera effect on tumorsphere 177 
TUBO and SKBR3-derived P1 tumorspheres were dissociated and cultured with or without sera from 178 
immunized mice (1:50) for 5 days. Spheres were counted, then processed for FACS. To measure 179 
ferroptosis, the iron chelator deferoxamine mesylate (DFO; 50 µM, Sigma-Aldrich) was added. After 180 
24 h, cells were stained with Annexin-V-APC kit and analyzed by FACS. 181 
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Cell migration assay 182 
TUBO and SKBR3 cells were treated for 1 h at 37°C in 100 μl of serum-free medium with or without 183 
sera (1:20) from vaccinated mice, then seeded (1×105 and 5×104, respectively, per well) in the top 184 
chamber of 24-Transwell plates (8-μm pore size; Corning). Medium with 10% FBS was inserted in 185 
bottom chambers, and cells were incubated at 37°C for 48 h. Cells on the top side of the filter were 186 
detached by brushing twice with cotton tipped swab. Cells migrated on the bottom side of the filter 187 
were fixed with 2.5% glutaraldehyde and stained with 0.2% crystal violet (Sigma-Aldrich). Four 188 
images per well were captured with an Olympus BX41 microscope and cells counted using Fiji and 189 
ImageJ softwares. 190 
MTT assay 191 
1×104 TUBO and SKBR3 cells were let adhere overnight in complete medium in 96-well plates. Sera 192 
(1:50) were then added, and cells incubated for 24, 48 or 72 h. MTT (0.5 mg/ml) was added for 4 h at 193 
37°C, then the supernatant was removed and 150 µl of dimethyl sulfoxide (Sigma Aldrich) added to 194 
dissolve formazan crystals. Absorbance was measured on a 680XR microplate reader (BioRad) at 195 
570 nm and 650 nm (background subtraction). 196 
Meta-analysis on patient databases 197 
For prognostic analyses, the Kaplan-Meier Plotter free software (http://kmplot.com/analysis/) (27) 198 
was used. Overall, relapse free and distant metastasis free survival data were presented as Kaplan – 199 
Meier plots and tested for significance using log-rank tests. Patients were stratified by expression of 200 
xCT (SLC7A11). To define the cutoff between high and low expression, all percentiles between the 201 
lower and upper quartiles were computed, and the best performing threshold was used as a cutoff 202 
through “auto select best cutoff” function. Analysis was restricted to Her2+ breast cancer samples. 203 
Statistical analysis 204 
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Statistical significance was evaluated using GraphPad8 software (GraphPad Inc.). Differences in 205 
tumor free mice were analyzed with Mantel-Cox log-rank test. Differences in sphere formation, 206 
FACS and ELISA data, metastasis and tumor multiplicity, cell migration and survival using two-207 






xCT expression is linked to poor prognosis in Her2+ breast cancer patients 212 
High levels of xCT expression are linked to poor prognosis in triple negative breast cancer patients 213 
(12). To analyze if the same was true for Her2+ breast cancer, we ran a meta-analysis on a set of 214 
publicly available microarray data from breast cancer patients (http://kmplot.com/analysis/) (27). 215 
Patients with high levels of xCT displayed a significantly lower overall and relapse-free survival as 216 
compared to patients displaying low levels of xCT expression (Fig. 1A, B), and a trend of decrease 217 
in distant metastasis-free survival (Fig. 1C). These results suggest that xCT plays a role in breast 218 
cancer progression, relapse and metastatic spreading, and prompted us to test whether its targeting 219 
may improve the outcome of anti-Her2 immunotherapies. 220 
xCT immunotargeting potentiates the effectiveness of anti-Her2 vaccination 221 
We have previously demonstrated that BoHV-4-xCT impairs breast CSCs and efficiently protects 222 
mice from cancer metastases in transplantable mammary cancer models (17). We therefore 223 
hypothesized that this vaccine may improve the outcome of Her2-targeted immunotherapies. To test 224 
this hypothesis, we selected the BALB-neuT mouse model, whose rat Her2/neu+ mammary tumors 225 
express xCT (Fig. 1D). BoHV-4-Her2, coding for a chimeric rat/human Her2, was used as Her2-226 
targeting immunotherapy, since we previously demonstrated that it can break BALB-neuT immune 227 
tolerance to Her2 (20). Female BALB-neuT mice were immunized by i.p. injections of 106 TCID50 228 
of BoHV-4-xCT, BoHV-4-Her2 and control vector (BoHV-4-ctrl), alone or in combination. All mice 229 
received 6 immunizations. Each vaccine was administered 4 times, and vaccination was performed 230 
every 2 weeks (Fig. 1E). Preliminary data showed that xCT expression is higher in 6 week-old BALB-231 
neuT mammary glands than in tumors at later stages (Supplementary Fig. S1). Furthermore, xCT is 232 
a key player both in the synthesis of GSH, which is necessary for cancer initiation but dispensable 233 
for its subsequent growth (28), and in the maintenance of CSCs, which are involved in tumor onset 234 
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(5). For these reasons, xCT immunotargeting was started in the early stages of tumor development 235 
(week 6), while Her2 immunotargeting was started at week 10, as previously reported (20).   236 
All vaccinated mice showed a significantly longer tumor-free survival (Fig. 1F) and a slower increase 237 
in tumor multiplicity than control mice (Fig. 1G). This effect was more pronounced in mice 238 
vaccinated with Her2, alone or in combination with xCT. Of note, xCT immunotargeting protected 239 
BALB-neuT mice from the development of lung metastases (Fig. 1H). Indeed, while all control and 240 
Her2 vaccinated mice displayed lung metastases, these were observed only in 50% and 54.5% of in 241 
mice vaccinated with Her2 + xCT or xCT alone, respectively. (Fig. 1H). Moreover, the number of 242 
lung metastases was significantly reduced by anti-xCT vaccination, alone or combined with Her2 243 
(Fig. 1I). Overall, these results demonstrate that xCT immunotargeting potentiates the effectiveness 244 
of anti-Her2 immunization by significantly hindering the development of metastases.  245 
xCT immunotargeting decreases CSC frequency in the tumors and lungs affected by metastases 246 
Since CSCs contribute to metastatic dissemination (5), we assessed the frequency of Sca1+ and CD44+ 247 
CD24- mammary CSCs in tumors and lungs from control and immunized mice. Sca1+ CSCs (29) 248 
were detected in both tumors and lungs of control mice. While their frequency was not reduced by 249 
anti-Her2 vaccination, it resulted significantly reduced by xCT immunotargeting, alone or combined 250 
with anti-Her2 vaccination (Fig. 2A, B). A different scenario was observed for the CD44+ CD24- CSC 251 
population, endowed with mesenchymal-like properties (30). A lower percentage of CD44+ CD24- 252 
CSCs was observed in the tumors of control and vaccinated mice as compared to the lungs (Fig. 2C, 253 
D). Moreover, while in the tumors no changes in the percentages of these cells were observed in 254 
vaccinated animals independently from the vaccine used (Fig. 2C), a strong decrease of CD44+ CD24- 255 
cells was observed in the lungs from mice vaccinated with Her2, xCT or both (Fig. 2D). These results 256 
confirm that xCT immunotargeting decreases CSC frequency and suggest a different sensitivity of 257 
the various CSC populations to Her2 targeting. 258 
Her2 and xCT combined immunotargeting activates tumor infiltrating T lymphocytes 259 
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To characterize the immune mechanisms that mediate the anti-tumor and anti-metastatic potential of 260 
anti-Her2 and anti-xCT combined immunotherapies, the immune cell infiltrate in the tumors and 261 
lungs of vaccinated mice was analyzed. None of the vaccines significantly increased the percentages 262 
of tumor infiltrating NK, NKT, and CD4+ T lymphocytes as compared to controls (Fig. 3A. B). 263 
However, all vaccines induced a significant increase in tumor infiltrating CD8+ T cells (black 264 
population in tSNE plots), which was more enhanced in mice vaccinated with Her2 + xCT (Fig. 3A, 265 
B). Moreover, all vaccines induced T cell activation in the tumors, as suggested by the significant 266 
increase in CD69+ cells in the total CD3+ T cell population. Of note, the combination of Her2 and 267 
xCT immunotargeting significantly increased T cell activation as compared to anti-Her2 vaccine 268 
alone. Activation was observed in both CD4+ (violet population in tSNE plots), and CD8+ (blue 269 
population in tSNE plots) T cells. Moreover, anti-xCT immunotargeting induced the activation of NK 270 
cells (Fig. 3A, C). On the contrary, the expression of PD-1 in NK and T cells was not significantly 271 
altered by any vaccine, although a trend of decrease in PD1+ CD4+ T cells (yellow population in tSNE 272 
plot) was observed in mice vaccinated with Her2 + xCT or xCT alone (Fig. 3A, D).  273 
None of the vaccines altered the frequency of NK, NKT or CD4+ T cells in lungs, while the 274 
combination of Her2 and xCT immunotargeting induced a significant increase in CD8+ T 275 
lymphocytes (Fig. 3E, F). All vaccination strategies induced the activation of NK, total CD3+ T and 276 
CD4+ T cells (violet population in tSNE plots), while CD8+ T cells were activated only by xCT 277 
immunotargeting, alone or in combination with anti-Her2 vaccination (Fig. 3E, G; blue population in 278 
tSNE plots). As for primary tumors, the treatments did not induce significant variations in the amount 279 
of PD-1+ NK or T cells (Fig. 3E, H).  280 
Overall, these data indicate that all the vaccines induce the activation of NK and CD4+ T cells in 281 
primary tumors and lungs, and of tumor-infiltrating CD8+ T lymphocytes, but xCT immunotargeting 282 
is the only one able to increase the frequency and the activation of CD8+ T lymphocytes in the lungs, 283 
suggesting a possible explanation for its anti-metastatic activity.  284 
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Anti-xCT vaccination induces xCT+ breast cancer cell cytotoxicity and decreases circulating 285 
Tregs 286 
To assess whether anti-Her2 and anti-xCT vaccination generates T lymphocytes able to kill breast 287 
cancer cells expressing Her2 and/or xCT antigens, we performed an in vitro cytotoxicity assay. SPC 288 
from the various groups were incubated with rat Her2+ TUBO, or triple negative 4T1 mammary 289 
cancer cells, at different E:T ratios. Both TUBO and 4T1 cells express xCT (Supplementary Fig. S2), 290 
while only TUBO cells express Her2. In accordance with the lack of high avidity Her2-specific CD8+ 291 
T cell clones in BALB-neuT mice due to central tolerance (31), SPC from Her2-vaccinated mice did 292 
not induce a significant cytotoxicity on TUBO cells and, as expected, on control 4T1 cells (Fig. 4A). 293 
On the contrary, anti-xCT vaccination induced a significant cytotoxicity of both cell lines, as 294 
previously observed in BALB/c mice (17). This effect was maintained when anti-xCT was associated 295 
with anti-Her2 vaccination (Fig. 4A), and was accompanied by a reduction of circulating Tregs, as 296 
compared to control mice (Fig. 4B). 297 
Her2 and xCT immunotargeting induces a specific antibody response that mediates ADCC 298 
The presence of Her2- and xCT-specific antibodies in the sera of mice two weeks after the last 299 
vaccination (18-week-old mice) was evaluated. Anti-xCT immunization induced the production of 300 
anti-xCT antibodies that were barely detectable in the sera from control and Her2-vaccinated mice 301 
(Fig. 5A). Of note, these antibodies were able to bind the xCT extracellular loops (Fig. 5B-F), 302 
suggesting that they can play a therapeutic role in vivo by directly binding to xCT on cancer cell 303 
surface. No differences were observed in the antibody titers between mice vaccinated with xCT alone 304 
or in combination with Her2, demonstrating that Her2 immunotargeting did not affect the response 305 
to xCT (Fig. 5A-F). Likewise, Her2 immunotargeting using the rat/human chimeric construct induced 306 
the generation of antibodies able to bind both the rat and human Her2 proteins (Fig. 5G, H). 307 
Surprisingly, anti-rat and human Her2 antibodies (Fig. 5G, H) were abundantly detected in the sera 308 
of mice vaccinated with xCT alone as well, suggesting that xCT immunotargeting in BALB-neuT 309 
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mice may induce immunogenic cancer cell death and epitope spreading. Similar results were obtained 310 
analyzing sera collected from 14-week-old mice (Supplementary Fig. S3). While the few anti-xCT 311 
antibodies present in control mice sera mainly belonged to the IgG1 isotype, vaccination induced the 312 
expansion of specific IgG2a antibodies (Fig. 5I). Similarly, the proportion of anti-Her2 IgG2a was 313 
increased by anti-Her2 vaccination as compared to control mice, with a concomitant reduction of the 314 
percentage of IgM and IgG3 (Fig. 5L). As IgG2a are the main responsible for ADCC in mice, vaccine-315 
induced anti-Her2 and anti-xCT antibodies were able to mediate ADCC of tumor cells by SPC from 316 
syngeneic mice. As expected, sera from Her2-immunized mice induced ADCC of TUBO but not of 317 
4T1 cells, while sera from xCT-vaccinated mice mediated ADCC of both cell lines. Of note, the 318 
combination of Her2 and xCT immunotargeting gave the best results on TUBO cells, since sera from 319 
mice vaccinated with Her2 + xCT induced a significantly higher ADCC than sera from mice treated 320 
with the single vaccines (Fig. 5M, N).   321 
Anti-Her2 and anti-xCT antibodies differentially impair cancer cell viability and migration 322 
Given that both anti-Her2 and anti-xCT vaccination induced a strong specific antibody response, we 323 
evaluated the direct effect that sera from vaccinated mice may exert on mammary cancer cells. TUBO 324 
cell viability was decreased after 48 and 72 h of incubation with sera from all groups of vaccinated 325 
mice, as compared to sera from control mice (Fig. 6A). To verify the possible translatability of this 326 
approach, sera were incubated with Her2+ human breast cancer SKBR3 cells, which express xCT 327 
(Supplementary Fig. S2). SKBR3 viability was impaired at a similar extent by incubation with the 328 
sera from Her2, Her2 + xCT and xCT vaccinated mice (Fig. 6B). These data demonstrate that 329 
vaccination induces antibodies that exert a direct impairment of cancer cell viability, contributing to 330 
the therapeutic effects observed in vivo.  331 
Since metastatic spreading was decreased in mice vaccinated with xCT, alone or in combination with 332 
Her2, the ability of vaccine-induced antibodies to inhibit cancer cell migration was assessed by 333 
transwell assays. As shown in Fig. 6C, sera from xCT or Her2 + xCT immunized mice significantly 334 
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impaired the migration of both Her2+ murine TUBO and human SKBR3 cells in vitro, as confirmed 335 
by the decreased number of migrating cells (Fig. 6D, F) and area covered by migrated cells (Fig. 6E, 336 
G). No effect was exerted by sera of mice vaccinated with Her2 alone (Fig. 6C-G), indicating that 337 
xCT and Her2 immunotargeting act with different mechanisms in hampering breast cancer 338 
progression, and supporting the anti-metastatic role exerted by xCT immunotargeting in vivo. 339 
Vaccine-induced xCT targeting antibodies halt CSCs increasing their ROS content, apoptosis 340 
and ferroptosis 341 
To further investigate the mechanisms underlying the different effects induced by anti-Her2 and anti-342 
xCT immunization on primary cancer growth and metastasis, we evaluated the ability of sera from 343 
immunized mice to target CSCs, which are considered as the main responsible for metastatic 344 
spreading. Cells derived from TUBO and SKBR3 CSC-enriched tumorspheres (23) were incubated 345 
with the sera. Sera from control mice did not alter second-generation tumorsphere formation, which 346 
was decreased by sera from Her2-vaccinated mice. A greater impairment of tumorsphere generation 347 
was induced by sera from xCT vaccinated mice and, even more, by sera from mice vaccinated with 348 
Her2 + xCT (Fig. 7A, B). This decreased CSC self-renewal potential in cells treated with sera from 349 
Her2 + xCT and xCT vaccinated mice was accompanied by a reduction in cells expressing the TUBO 350 
CSC marker Sca1+ (32) (Fig. 7C). Similar results were obtained in SKBR3 tumorspheres, where sera 351 
from Her2 and, even more, from Her2 + xCT or xCT immunized mice significantly reduced the ratio 352 
between the percentage of CD44+ and CD24+ cells (Fig. 7D), which correlates with stemness in this 353 
cell line (33). Since xCT plays a key role in the maintenance of CSC redox balance (10), intracellular 354 
ROS content was evaluated. While ROS content of either TUBO or SKBR3 tumorspheres was not 355 
altered by control or Her2-vaccinated mice sera, ROS were significantly increased in tumorspheres 356 
treated with sera from mice vaccinated against Her2 + xCT or xCT alone (Fig. 7E and F). Moreover, 357 
these sera were able to induce apoptosis in CSCs from both cell lines, while sera from control or 358 
Her2-immunized mice had no effect (Fig. 7G, H). Sera from Her2 + xCT- or xCT-vaccinated mice 359 
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were also able to induce ferroptosis in both TUBO and SKBR3 CSCs, as demonstrated by the ability 360 
of the iron chelating agent deferoxamine (DFO) of rescuing cells from the cytotoxic effect induced 361 
by these sera. On the contrary, sera from control or Her2-vaccinated mice did not induce cell death 362 
either in the absence or presence of DFO (Fig. 7I, L).  363 
Overall, these data demonstrate that anti-xCT vaccination is more effective than Her2 364 
immunotargeting in reducing the CSC population, making their combination of great interest for 365 
breast cancer treatment. 366 
 367 
Discussion 368 
The introduction of Her2-targeted therapies in the clinical practice has significantly improved the 369 
outcome of Her2+ breast cancer patients. However, most patients display primary resistance or relapse 370 
after treatment, and metastatic breast cancer is considered incurable with current therapies (34). 371 
Therefore, the setup of combined therapeutic protocols able to target the mechanisms and cell 372 
populations involved in the resistance to Her2-targeted therapies and prevent metastatic spreading is 373 
urgently needed to improve treatment efficacy. Therapies able to eradicate CSCs, which are implied 374 
in the resistance to most current therapies, including Her2-targeted therapies (4,5), may thus synergize 375 
with Her2-directed drugs and reinstate cancer sensitivity to treatment.  376 
To this end, we have developed a combined vaccination approach targeting both Her2 and the CSC-377 
associated antigen xCT, using BoHV-4-based viral vectors. We tested this immunotherapy in BALB-378 
neuT mice, which represent an ideal model to study new therapies for Her2+ breast cancer in virtue 379 
of the high homology of their tumors to the human counterpart (19) and of the fact that their tumors 380 
contain cells that can disseminate to the bone marrow early after the activation of Her2 transcription, 381 
and then move to the lungs where they give rise to overt metastasis (35,36). 382 
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Her2 and xCT represent self-antigens in BALB-neuT mice. Nevertheless, BoHV-4-based vaccination 383 
was able to induce a strong and specific immune response to both of them. As expected, Her2 384 
immunotargeting induced mainly a humoral response, along with the activation of NK and T helper 385 
cells in both primary tumors and lung metastases. However, no increase of activation was observed 386 
in lung-infiltrating CD8+ T lymphocytes. On the contrary, anti-xCT vaccination was able to induce 387 
both a polyclonal antibody response and the activation of tumor- and lung-infiltrating NK, CD4+ and 388 
CD8+ T cells. In accordance to this pattern of immune response, anti-xCT but not anti-Her2 389 
vaccination induced cytotoxic T cells able to kill breast cancer cells. The lack of Her2-directed 390 
cytotoxicity is due to the thymic deletion of high avidity Her2-specific CD8+ T cell clones in BALB-391 
neuT mice (31). A CD4+ T cell repertoire is instead generated and escapes central tolerance (31), thus 392 
allowing the induction of an anti-Her2 antibody response that is necessary for protection from 393 
autochthonous tumor development (19,20,37). BoHV-4-based anti-xCT vaccination, instead, is able 394 
to break immune tolerance and induce a T cytotoxic response, which we previously demonstrated to 395 
exert a key role in vivo in transplantable models of mammary cancer (17). While naive T lymphocytes 396 
lack xCT and rely on the uptake of cysteine released from antigen presenting cells for the synthesis 397 
of GSH, xCT expression is induced on T lymphocytes upon activation and is necessary for their 398 
proliferation in vitro (38). However, in vivo compensative mechanisms make xCT dispensable for T 399 
cell proliferation and anti-tumoral responses (39), allowing the induction of T cell responses in xCT-400 
vaccinated mice. Of note, the induction of xCT-specific cytotoxic T cells is exclusive of BoHV-4-401 
based vaccine, since neither DNA nor Virus-like particle-based vaccines exert the same effect (7,18), 402 
indicating that this vaccine formulation is superior in breaking immune tolerance to self-antigens. 403 
This is likely due to viral vectors’ intrinsic immunogenicity, which creates an inflammatory 404 
environment that potentiates T lymphocyte activation (40). Moreover, xCT immunotargeting 405 
decreased Tregs frequency. This may be due to the reduction in glutamate export from xCT 406 
expressing cells, which would prevent the proliferative effect exerted by metabotropic glutamate 407 
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receptor 1 on Tregs (8), although further studies are needed to evaluate possible direct effects of xCT 408 
targeting on this cell population.  409 
Her2 and xCT immunotargeting induced a strong antibody response. Of note, anti-xCT vaccination 410 
induced epitope spreading, with the production of antibodies able to recognize rat Her2 and react with 411 
human Her2. A similar phenomenon was previously observed using a DNA vaccine coding for the 412 
extracellular and transmembrane domain of rat Her2, which was able to induce an early spread of the 413 
immune response to Her2 intracellular epitopes (31) and antibodies able to recognize human Her2 414 
(37). Vaccine-induced antibodies exerted both direct and indirect effects on cancer cells, inducing 415 
ADCC and directly affecting their viability. The induction of an antibody response is particularly 416 
important for the elimination of CSCs, which downregulate MHC class I and become therefore less 417 
sensitive to T cell killing (32). Indeed, sera from vaccinated mice, and in particular from mice 418 
vaccinated with xCT alone or in combination with Her2, strongly inhibited CSC self-renewal in vitro 419 
and altered their redox balance, inducing ROS accumulation and ferroptosis. 420 
Anti-Her2 immunotargeting was effective in inhibiting primary tumor growth, with limited effects 421 
on metastasis. Instead, anti-xCT vaccination strongly impaired CSC self-renewal, decreased cancer 422 
cell survival and migration, thus preventing metastasis formation. Although the complex mechanisms 423 
underpinning cancer metastasis formation have not been completely dissected, recent data showed 424 
that metastatic dissemination often occurs during the early phases of cancer progression, when the 425 
frequency of CSCs in primary lesions is higher than in more advanced tumors (35). In transgenic 426 
Her2+ mammary cancer mouse models, 80% of metastases derive from early disseminated cancer 427 
cells, which display moderate levels of Her2 and high progesterone receptor expression. These cells 428 
possess CSC features, such as Wnt pathway activation, inhibition of p38 activation and of E-cadherin- 429 
and -catenin-mediated junction formation, thus allowing for an epithelial-to-mesenchymal transition 430 
(EMT)-like invasive program (35,41). Of note, by decreasing intracellular ROS content, xCT inhibits 431 
p38 activation, thus diminishing caveolin-1 and the subsequent recruitment of -catenin to the plasma 432 
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membrane, suggesting that xCT may contribute to the invasive properties of disseminating cells (42). 433 
Indeed, we have preliminary data showing that early disseminated cancer cells present in the bone 434 
marrow of 7-week-old BALB-neuT mice express xCT. Therefore, xCT immunotargeting may hinder 435 
metastasis formation by inducing the eradication of early disseminated cancer cells and CSCs that are 436 
responsible for tumor spreading to distal organs. On the contrary, Her2 expression is low in early 437 
lesions and in early disseminated cancer cells, while it increases during cancer growth, and Her2 438 
activation seems to be more involved in the proliferation of disseminated cells than in their migration 439 
(35). Moreover, despite several reports indicating that Her2 promotes breast CSC self-renewal (43), 440 
different groups have demonstrated that Her2 inhibition leads to Notch1 activation, thus promoting 441 
CSC expansion and tumor recurrence and metastasis (44,45). Indeed, CSCs from SKBR3 cells are 442 
resistant to Her2-targeted therapies (46), in accordance with our data showing that antibodies from 443 
Her2-vaccinated mice exert only a mild inhibitory effect on SKBR3 tumorspheres, which are 444 
effectively inhibited by antibodies from xCT-vaccinated mice. Overall, our data and evidences from 445 
the literature suggest that Her2 and xCT immunotargeting may act synergistically, with anti-Her2 446 
immune response mainly affecting cancer growth, and anti-xCT immune reaction hindering 447 
metastatic spreading. 448 
While Her2-directed immunotherapy are currently used in the clinical practice, the clinical 449 
translatability of xCT immunotargeting may be questioned by its nature of cancer-associated antigen 450 
also expressed on astrocytes, some myeloid cell types and activated T cells (10). However, the safety 451 
of xCT targeting is supported by the lack of organ alterations, developmental and immunological 452 
defects in xCT knockout mice (39,47) and in Subtle grey mice harboring a spontaneous protein null 453 
mutation in the xCT allele (48). Indeed, the xCT inhibitor SAS is widely used for the treatment of 454 
inflammatory diseases such as Crohn’s disease and ulcerative colitis (49). Moreover, no adverse 455 
events were observed here in xCT-vaccinated BALB-neuT mice or previously in xCT-vaccinated 456 
BALB/c mice (7,17), and no alterations or immune infiltration were observed in the central nervous 457 
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system of mice vaccinated with xCT-targeting virus-like particles (18). Therefore, the possibility of 458 
targeting xCT for cancer treatment has recently attracted the attention of pharmaceutical companies 459 
(39). 460 
The recent clinical successes of checkpoint blocking antibodies and of chimeric antigen receptor T 461 
cells has opened a new golden age for cancer immunotherapy, leading many researchers to focus on 462 
these new immunotherapies. However, we believe that vaccination still represents a promising 463 
approach, since the activation of antigen-specific anti-tumor responses may effectively hamper cancer 464 
progression (3). In this article, we chose to target both Her2 and xCT with vaccination. Although we 465 
think that anti-xCT vaccination can improve the effectiveness of any of the current Her2-targeted 466 
therapies, and we are conscious that monoclonal antibodies and molecular inhibitors currently play a 467 
major role in Her2-targeted therapies, we think that anti-Her2 vaccination should still be kept in high 468 
consideration for cancer treatment. Indeed, vaccination is a cost-effective strategy as compared to 469 
more expensive monoclonal antibodies and lymphocyte adoptive therapies. Breast cancer incidence 470 
is rapidly increasing in low- and middle-income countries, where the lack of resources and 471 
investments makes breast cancer a neglected disease, causing high mortality rates and health inequity 472 
(1). The development of effective anti-Her2 vaccines might provide more affordable and accessible 473 
therapies able to improve life expectancy of hundreds of thousands of women that currently have to 474 
face disability and premature death from breast cancer. In this view, BoHV-4 represents a promising 475 
vector in virtue of its absence of pathogenicity or oncogenic activity, the possibility of performing 476 
repeated boosts without inducing virus neutralizing antibodies, and its ability to induce a strong 477 
immune response able to break tolerance to cancer-associated antigens (50). 478 
In conclusion, our findings demonstrate that xCT immunotargeting synergizes with Her2-directed 479 
immunotherapy in hampering breast cancer progression and metastasis. Indeed, while Her2 480 
immunotargeting mainly impairs the growth of primary tumor, anti-xCT vaccination strongly affects 481 
CSCs and inhibits the generation of lung metastases. This combinatorial immunotherapeutic approach 482 
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could be combined with treatments such as immune checkpoint inhibitors or chemotherapy to further 483 
induce anti-cancer immune responses, opening new perspectives in the management of Her2+ breast 484 
cancer. 485 
 486 
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Figure 1. xCT is related to poor prognosis in Her2+ breast cancer patients, and its
immunotargeting potentiates anti-Her2 vaccination in BALB-neuT mice.
(A-C) Kaplan – Meier plots displaying overall (A), relapse-free (B) and distant metastasis-free (C)
survival in Her2+ breast cancer patients stratified according to xCT mRNA expression. (D)
Representative FACS analysis of xCT (red) or control Ab (grey) on a mammary tumor explanted
from a BALB-neuT mouse. (E) Schematic representation of the immunization protocol of control
BALB-neuT mice or mice vaccinated 6 times, every 2 weeks, with 106 TCID50 of BoHV-4-ctrl and
BoHV-4-Her2 (Her2); BoHV-4-xCT and BoHV-4-Her2 (Her2 + xCT); BoHV-4-xCT and BoHV-4-
ctrl (xCT). (N=11 per group). (F) Tumor-free survival and (G) tumor multiplicity in control or
immunized BALB-neuT mice. (H) Relative percentage of mice that developed (black) or not (grey)
lung metastases. (I)Mean ± SEM of the number of superficial lung metastases observed in control or
immunized mice. Each dot represents a single mouse. *, P < 0.05; **, P < 0.01, ***, P < 0.001; (A-C,
F) Log-rank Mantel-Cox or (G, I) Student’s t tests.
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Figure 2. xCT immunotargeting decreases CSC frequency in BALB-neuT tumors and lungs. FACS
analysis of (A, B) Sca1+ and (C, D) CD44+ CD24- CSC populations in (A, C) tumors and (B, D) lungs
from control mice or mice treated with anti-Her2, anti-Her2 + anti-xCT, or anti-xCT vaccines.
Representative dot plots and graphs showing the mean ± SEM of the percentage of CD45- cells
expressing the CSC markers are shown. In graphs, each dot represents a single mouse. At least 6 mice
per group were analyzed. *, P < 0.05; **, P < 0.01, Student’s t test.
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Figure 3. Her2 and xCT immunotargeting induces the activation of T lymphocytes in the tumors
and lungs of vaccinated mice. FACS analysis of immune infiltrates in (A-D) tumors and (E-H) lungs
of control BALB-neuT mice or mice immunized with anti-Her2, anti-Her2 + anti-xCT, or anti-xCT
vaccines. (A, E) tSNE analysis run on 5000 live CD45+ single cells per sample, on 5 samples per group.
tSNE maps show concatenated FCS3 files for each group of mice, with the overlay of manually gated
cell populations. (B, F) Graphs showing the percentage ± SEM of CD45+ cells expressing the markers
of NK (CD3− CD49b+), NKT (CD3+ CD49b+), CD4+ (CD3+ CD49b- CD4+) and CD8+ (CD3+ CD49b-
CD8+) T cell populations. Percentage ± SEM of (C, G) CD69+ and (D, H) PD1+ cells among T and NK










































































Figure 4. Anti-xCT vaccination induces T cell cytotoxicity of xCT+ breast cancer cells and
decreases circulating Treg cells. (A) SPC from control or vaccinated mice (N=4 per group) were
co-cultured at different E:T ratios (200, 100 or 50:1) with CFSE+ TUBO or 4T1 cells for 48 h. The
percentage of 7-AAD+ dead cells among CFSE+ cells was analyzed by FACS. Graphs show means ±
SEM of the percentages of specific lysis. *, P < 0.05, **, P < 0.01: Her2 + xCT vs Her2 or control.
°, P < 0.05, °°, P < 0.01: xCT vs Her2 or control. +, P < 0.05; ++, P < 0.01, Her2 vs control; Student’s
t-test. (B) Means ± SEM of the percentage of Tregs (CD3+ CD4+ CD25high GITR+ Foxp3+) among
CD4+ T lymphocytes analyzed at sacrifice in the peripheral blood of BALB-neuT mice (N ≥ 5 mice





















































































































































































Figure 5. xCT and Her2 immunotargeting induces specific humoral responses that induce ADCC.
Pooled sera from control or vaccinated BALB-neuT mice were tested by ELISA on (A) mouse xCT protein;
peptides representing mouse xCT extracellular loops (B) 1, (C) 2, (D) 3, (E) 4 or (F) 6; the recombinant
extracellular domains of (G) rat or (H) human Her2 proteins. Graphs show means ± SEM of two pools
analyzed from 3 independent experiments. *, P < 0.05; **, P < 0.01, ***, P < 0.001, Student’s t test. (I, L)
Proportion of (I) anti-xCT and (L) anti-Her2 Ig isotypes analyzed by ELISA in the sera of control or
vaccinated mice. (M, N) ADCC analyzed in vitro on CFSE+ (M) TUBO or (N) 4T1 target cells incubated
with a 1:50 dilution of sera pooled from control or vaccinated mice and SPC from naive mice at different
E:T ratios (200, 100, and 50:1). Results shown are the mean ± SEM of the percentage of ADCC. Statistical
analysis was performed with Student’s t test as follows; +, Control vs Her2. *, Control vs Her2 + xCT. °,
Control vs xCT. $, Her2 vs Her2 + xCT. §, xCT vs Her2 + xCT. #, xCT vs Her2 + xCT. 1 symbol, P < 0.05; 2
symbols, P < 0.01; 3 symbols, P < 0.001; 4 symbols, P < 0.0001.
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Figure 6. Anti-Her2 and anti-xCT antibodies differentially impair cancer cell viability and
migration. MTT analysis of cell viability of (A) TUBO and (B) SKBR3 cells incubated for 24, 48 and
72 h with a 1:50 dilution of sera pooled from control or vaccinated BALB-neuT mice. Results are
shown as means ± SEM of the percentage of cell viability compared to cells incubated with control
sera, from 3 independent experiments. (C-G) Effect of sera on cell migration assessed using the
Transwell migration assay on TUBO and SKBR3 cells. (C) Representative images of cells migrated to
the lower surface of the transwell filter and stained with crystal violet. Graphs show the means ± SEM
of (D, F) the number of migrated cells and (E, G) the % of area covered by migrated cells, counted in
five different fields. A representative experiment out of three is shown. *, P < 0.05; **, P < 0.01, ***, P
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Figure 7. Vaccination-induced anti-xCT antibodies target CSCs by increasing ROS, apoptosis and
ferroptosis. (A-H) Cells dissociated from tumorspheres generated from TUBO or SKBR3 cells were
incubated for 5 days with medium, or with a 1:50 dilution of sera pooled from control or vaccinated
mice. (A, B) Sphere generating ability reported as number of second passage tumorspheres generated
every 103 plated cells. (C) Means ± SEM of the percentage of Sca1+ cells analyzed by FACS in TUBO
tumorspheres. (D) Means ± SEM of the ratio between the percentage of CD44+ and CD24- cells
quantified by FACS in SKBR3 tumorspheres. (E, F) FACS analysis of intracellular ROS content,
reported as means ± SEM of DCF MFI. (G-H) FACS analysis of apoptosis, reported as mean ± SEM of
the fold increase of Annexin V+ cells compared to tumorspheres cultured in medium alone. (I-L)
Analysis of ferroptosis in cells dissociated from tumorspheres generated from TUBO or SKBR3 cells
and incubated for 24 h with medium, or with sera from control or vaccinated mice (1:50), in the absence
or presence of the iron chelator DFO (50 µM). Means ± SEM of the percentage of Annexin V-
/propidium iodide (PI)+ cells is reported. Each dot represents an independent experiment. *, P < 0.05;
**, P < 0.01, ***, P < 0.001, ****, P < 0.0001, Student’s t test.
